David M. Knott’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$69K Hold
300
0.03% 128
2021
Q2
$69K Hold
300
0.02% 125
2021
Q1
$56K Hold
300
0.02% 112
2020
Q4
$51K Hold
300
0.02% 90
2020
Q3
$44K Hold
300
0.03% 83
2020
Q2
$49K Hold
300
0.03% 80
2020
Q1
$42K Hold
300
0.03% 107
2019
Q4
$39K Hold
300
0.02% 102
2019
Q3
$34K Hold
300
0.01% 104
2019
Q2
$33K Hold
300
0.01% 99
2019
Q1
$39K Hold
300
0.02% 100
2018
Q4
$35K Hold
300
0.02% 91
2018
Q3
$32K Hold
300
0.01% 96
2018
Q2
$26K Hold
300
0.01% 102
2018
Q1
$23K Hold
300
0.01% 101
2017
Q4
$25K Hold
300
0.01% 104
2017
Q3
$26K Hold
300
0.01% 99
2017
Q2
$25K Hold
300
0.01% 82
2017
Q1
$25K Hold
300
0.01% 71
2016
Q4
$22K Hold
300
0.01% 65
2016
Q3
$24K Hold
300
0.01% 55
2016
Q2
$23.6K Sell
300
-21,303
-99% -$1.6M 0.01% 72
2016
Q1
$25.1K Buy
21,603
+21,303
+7,101% +$1.61M 0.01% 72
2015
Q4
$25.3K Hold
300
0.01% 70
2015
Q3
$25.1K Hold
300
0.01% 69
2015
Q2
$25K Hold
300
0.01% 76
2015
Q1
$21.8K Hold
300
﹤0.01% 80
2014
Q4
$20.7K Hold
300
﹤0.01% 71
2014
Q3
$19.5K Hold
300
﹤0.01% 75
2014
Q2
$18.7K Hold
300
﹤0.01% 77
2014
Q1
$17.7K Hold
300
﹤0.01% 62
2013
Q4
$15.3K Hold
300
﹤0.01% 63
2013
Q3
$15.1K Buy
+300
New +$15.7K ﹤0.01% 69

Other funds holding LLY

David M. Knott's LLY Position: Q3 2021 in Review

David M. Knott held its Eli Lilly (LLY) position steady in Q3 2021 at 300 shares worth $69K. The position accounts for 0.03% of the portfolio, ranked #128.

David M. Knott first reported a position in LLY in Q3 2013 and has held it in 33 quarters since. 2,051 funds tracked by Wall St. Rank hold LLY as of Q3 2021.

  • David M. Knott held 300 shares of Eli Lilly worth $69K as of Q3 2021.
  • David M. Knott left its Eli Lilly share count unchanged in Q3 2021.
  • Eli Lilly made up 0.03% of David M. Knott's portfolio in Q3 2021, its #128 holding.
  • David M. Knott first reported a position in Eli Lilly in Q3 2013 and has held it in 33 quarters since.
  • 2,051 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.